---
annotation-target: blood.2022016963.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-17T02:49:09.829Z","updated":"2022-09-17T02:49:09.829Z","document":{"title":"blood.2022016963.pdf","link":[{"href":"urn:x-pdf:63c75cdd3e85533b2e9042ff23f120cc"},{"href":"vault:/hematology-theroy/papers/20220917/blood.2022016963.pdf"}],"documentFingerprint":"63c75cdd3e85533b2e9042ff23f120cc"},"uri":"vault:/hematology-theroy/papers/20220917/blood.2022016963.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220917/blood.2022016963.pdf","selector":[{"type":"TextPositionSelector","start":7519,"end":7529},{"type":"TextQuoteSelector","exact":" VIALE-C  ","prefix":"vision Long-term  follow-up  of ","suffix":"in  patients  with  untreated  A"}]}]}
>```
>%%
>*%%PREFIX%%vision Long-term  follow-up  of%%HIGHLIGHT%% ==VIALE-C== %%POSTFIX%%in  patients  with  untreated  A*
>%%LINK%%[[#^m528ekhkrhf|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^m528ekhkrhf


>%%
>```annotation-json
>{"created":"2022-09-17T02:49:17.889Z","updated":"2022-09-17T02:49:17.889Z","document":{"title":"blood.2022016963.pdf","link":[{"href":"urn:x-pdf:63c75cdd3e85533b2e9042ff23f120cc"},{"href":"vault:/hematology-theroy/papers/20220917/blood.2022016963.pdf"}],"documentFingerprint":"63c75cdd3e85533b2e9042ff23f120cc"},"uri":"vault:/hematology-theroy/papers/20220917/blood.2022016963.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220917/blood.2022016963.pdf","selector":[{"type":"TextPositionSelector","start":7580,"end":7604},{"type":"TextQuoteSelector","exact":"  intensive chemotherapy","prefix":" untreated  AML  ineligible  for","suffix":"  Andrew  H.  Wei1,  Panayiotis "}]}]}
>```
>%%
>*%%PREFIX%%untreated  AML  ineligible  for%%HIGHLIGHT%% ==intensive chemotherapy== %%POSTFIX%%Andrew  H.  Wei1,  Panayiotis*
>%%LINK%%[[#^qa57rbs5xvh|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^qa57rbs5xvh


>%%
>```annotation-json
>{"created":"2022-09-17T02:50:20.864Z","updated":"2022-09-17T02:50:20.864Z","document":{"title":"blood.2022016963.pdf","link":[{"href":"urn:x-pdf:63c75cdd3e85533b2e9042ff23f120cc"},{"href":"vault:/hematology-theroy/papers/20220917/blood.2022016963.pdf"}],"documentFingerprint":"63c75cdd3e85533b2e9042ff23f120cc"},"uri":"vault:/hematology-theroy/papers/20220917/blood.2022016963.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220917/blood.2022016963.pdf","selector":[{"type":"TextPositionSelector","start":10609,"end":12864},{"type":"TextQuoteSelector","exact":"Venetoclax  (VEN)  in  combination  with  low  dose  cytarabine  (LDAC)  is  FDA-approved  for  the treatment  of  unfit  patients  with  newly  diagnosed  AML  ineligible  for  intensive  chemotherapy, based on a response rate of 54% (complete remission with or without blood count recovery [CR/CRi])  in  the  original  phase  Ib/II  study.1    The  VIALE-C  phase  3  study  (NCT03069352), compared VEN vs placebo (PBO) in combination with LDAC in 210 patients with untreated AML ineligible for intensive chemotherapy.2,3 The primary overall survival (OS) endpoint was event-driven and did not show a significant benefit in favor of VEN + LDAC after a median follow-up time  of  12  months.2  This  initial  analysis  was  associated  with  substantial  early  censoring  of patients with <6 months follow-up. In a subsequent post hoc analysis with median follow-up 17.5 months (range 0.1 – 23.5), median OS was significantly longer in patients receiving VEN + LDAC (8.4 vs. 4.1 months; HR = 0.70, 95% CI 0.50, 0.99; P = 0.04). Rates of CR/CRi were higher for patients receiving VEN + LDAC (48.3%), compared to PBO + LDAC (13.2%). In the present study, a final analysis with 2-years additional follow-up was undertaken to determine if the survival benefit of VEN +LDAC was sustained. In addition, clinical and molecular correlates of  survival  among  patients  receiving  VEN  +  LDAC  were  assessed.  These  analyses demonstrated  that  survival  outcome  was  influenced  by  prior  exposure  to  hypomethylating agents,  clinical  response,  cytogenetic  risk  and  molecular  genotype,  with  best  outcomes observed for patients with NPM1 mutation. This longer-term final analysis confirmed the survival improvement of VEN + LDAC in patients unfit for intensive chemotherapy.  At last follow-up on 15 February 2021 (median follow-up 34.7 months; range 0.1 – 41.3), 83.9% (n = 120; Ven + LDAC) and 89.7% (n = 61; PBO + LDAC) of patients had died with 7% of patients  (n  =10)  still  receiving  Ven  +  LDAC.  No  patient  was  receiving  LDAC  +  PBO  at  this follow-up. Two patients on Ven + LDAC were lost to follow-up, and five withdrew consent (VEN + LDAC 3 [2.1%] and PBO + LDAC 2 [2.9%]). With an additional 2 years of follow-up from the ","prefix":"AC for untreated AML   Revision ","suffix":"Downloaded from http://ashpublic"}]}]}
>```
>%%
>*%%PREFIX%%AC for untreated AML   Revision%%HIGHLIGHT%% ==Venetoclax  (VEN)  in  combination  with  low  dose  cytarabine  (LDAC)  is  FDA-approved  for  the treatment  of  unfit  patients  with  newly  diagnosed  AML  ineligible  for  intensive  chemotherapy, based on a response rate of 54% (complete remission with or without blood count recovery [CR/CRi])  in  the  original  phase  Ib/II  study.1    The  VIALE-C  phase  3  study  (NCT03069352), compared VEN vs placebo (PBO) in combination with LDAC in 210 patients with untreated AML ineligible for intensive chemotherapy.2,3 The primary overall survival (OS) endpoint was event-driven and did not show a significant benefit in favor of VEN + LDAC after a median follow-up time  of  12  months.2  This  initial  analysis  was  associated  with  substantial  early  censoring  of patients with <6 months follow-up. In a subsequent post hoc analysis with median follow-up 17.5 months (range 0.1 – 23.5), median OS was significantly longer in patients receiving VEN + LDAC (8.4 vs. 4.1 months; HR = 0.70, 95% CI 0.50, 0.99; P = 0.04). Rates of CR/CRi were higher for patients receiving VEN + LDAC (48.3%), compared to PBO + LDAC (13.2%). In the present study, a final analysis with 2-years additional follow-up was undertaken to determine if the survival benefit of VEN +LDAC was sustained. In addition, clinical and molecular correlates of  survival  among  patients  receiving  VEN  +  LDAC  were  assessed.  These  analyses demonstrated  that  survival  outcome  was  influenced  by  prior  exposure  to  hypomethylating agents,  clinical  response,  cytogenetic  risk  and  molecular  genotype,  with  best  outcomes observed for patients with NPM1 mutation. This longer-term final analysis confirmed the survival improvement of VEN + LDAC in patients unfit for intensive chemotherapy.  At last follow-up on 15 February 2021 (median follow-up 34.7 months; range 0.1 – 41.3), 83.9% (n = 120; Ven + LDAC) and 89.7% (n = 61; PBO + LDAC) of patients had died with 7% of patients  (n  =10)  still  receiving  Ven  +  LDAC.  No  patient  was  receiving  LDAC  +  PBO  at  this follow-up. Two patients on Ven + LDAC were lost to follow-up, and five withdrew consent (VEN + LDAC 3 [2.1%] and PBO + LDAC 2 [2.9%]). With an additional 2 years of follow-up from the== %%POSTFIX%%Downloaded from http://ashpublic*
>%%LINK%%[[#^ygkg4yv7d0q|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ygkg4yv7d0q


>%%
>```annotation-json
>{"created":"2022-09-17T02:50:56.756Z","updated":"2022-09-17T02:50:56.756Z","document":{"title":"blood.2022016963.pdf","link":[{"href":"urn:x-pdf:63c75cdd3e85533b2e9042ff23f120cc"},{"href":"vault:/hematology-theroy/papers/20220917/blood.2022016963.pdf"}],"documentFingerprint":"63c75cdd3e85533b2e9042ff23f120cc"},"uri":"vault:/hematology-theroy/papers/20220917/blood.2022016963.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220917/blood.2022016963.pdf","selector":[{"type":"TextPositionSelector","start":16072,"end":16604},{"type":"TextQuoteSelector","exact":"longer-term  follow-up confirmed that patients receiving VEN + LDAC  had longer median OS than patients receiving PBO + LDAC.  CR/CRi responses in the VEN + LDAC were durable, with  31.6%  remaining  in  remission  for  >2  years.  Notably,  for  patients  with  NPM1  mutation treated with VEN + LDAC, OS at 24 months was ~50%. In contrast, outcomes for patients with TP53  mutation  remained  poor.  This  2-year  follow-up  analysis  confirms  long-term  benefit  for patients treated with VEN + LDAC, with no new safety findings","prefix":"ble for intensive chemotherapy, ","suffix":".  Data sharing statement AbbVie"}]}]}
>```
>%%
>*%%PREFIX%%ble for intensive chemotherapy,%%HIGHLIGHT%% ==longer-term  follow-up confirmed that patients receiving VEN + LDAC  had longer median OS than patients receiving PBO + LDAC.  CR/CRi responses in the VEN + LDAC were durable, with  31.6%  remaining  in  remission  for  >2  years.  Notably,  for  patients  with  NPM1  mutation treated with VEN + LDAC, OS at 24 months was ~50%. In contrast, outcomes for patients with TP53  mutation  remained  poor.  This  2-year  follow-up  analysis  confirms  long-term  benefit  for patients treated with VEN + LDAC, with no new safety findings== %%POSTFIX%%.  Data sharing statement AbbVie*
>%%LINK%%[[#^olleh2v3vy|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^olleh2v3vy
